[Anti-NMDA receptor encephalitis: two paediatric cases]
M Cristina González-Toro1, Rocío Jadraque-Rodríguez, Ángela Sempere-Pérez
1Hospital General Universitario de Alicante, 03010 San Vicente del Raspeig, Espana.
Anti-NMDA receptor encephalitis is a treatable autoimmune disorder in children. Early diagnosis and treatment are crucial for improved outcomes and reduced relapse risk.
Area of Science:
- Neurology
- Immunology
- Pediatrics
Background:
- Anti-N-methyl-D-aspartate (NMDA) receptor antibody encephalitis is an increasingly recognized autoimmune neurological disorder in children.
- This condition presents with diverse neurological and psychiatric symptoms, posing diagnostic challenges.
Observation:
- Two pediatric cases are presented with similar clinical presentations.
- Case 1: A 5-year-old girl with seizures, altered consciousness, movement disorders, and autistic regression.
- Case 2: A 13-year-old girl with hemiparesis, abnormal movements, conduct disorder, and dysautonomia.
Findings:
- Both patients tested positive for anti-NMDA receptor antibodies in cerebrospinal fluid.
- Treatment involved corticosteroids, immunoglobulins, and rituximab in one case.
- Both patients showed favorable outcomes, with residual language disorder in one and a resolved relapse in the other.
Implications:
- Anti-NMDA receptor encephalitis is a treatable condition.
- Early diagnosis and prompt treatment significantly improve patient prognosis.
- Timely intervention can reduce the likelihood of disease relapses.
More Related Videos
07:20A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
08:20Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
Related Concept Videos
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Arboviral Encephalitis
Viral Meningitis
Bacterial Meningitis II: Pathophysiology
Antiepileptic Drugs: Glutamate Antagonists
